logo
explain how to read the page

The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers 2
  • 1
    Zhang, Lingyan
    Director born in January 1972
    Individual (1 offspring)
    Officer
    2015-03-23 ~ 2017-12-18
    OF - Director → CIF 0
  • 2
    Peng, Huai Zheng, Dr
    Born in November 1962
    Individual (6 offsprings)
    Officer
    2014-12-17 ~ now
    OF - Director → CIF 0
parent relation
Company in focus

BRIDGING PHARMA LTD

Period: 2014-12-17 ~ now
Company number: 09359212
Registered name
BRIDGING PHARMA LTD - now
Standard Industrial Classification
96090 - Other Service Activities N.e.c.
Brief company account
Debtors
27,911 GBP2024-12-31
51,331 GBP2023-12-31
Cash at bank and in hand
183,306 GBP2024-12-31
157,357 GBP2023-12-31
Current Assets
211,217 GBP2024-12-31
208,688 GBP2023-12-31
Creditors
Current
193,473 GBP2024-12-31
356,390 GBP2023-12-31
Net Current Assets/Liabilities
17,744 GBP2024-12-31
-147,702 GBP2023-12-31
Total Assets Less Current Liabilities
17,744 GBP2024-12-31
-147,702 GBP2023-12-31
Equity
Called up share capital
100 GBP2024-12-31
100 GBP2023-12-31
100 GBP2022-12-31
Retained earnings (accumulated losses)
17,644 GBP2024-12-31
-147,802 GBP2023-12-31
-165,209 GBP2022-12-31
Equity
17,744 GBP2024-12-31
-147,702 GBP2023-12-31
-165,109 GBP2022-12-31
Comprehensive Income/Expense
Retained earnings (accumulated losses)
165,446 GBP2024-01-01 ~ 2024-12-31
17,407 GBP2023-01-01 ~ 2023-12-31
Comprehensive Income/Expense
165,446 GBP2024-01-01 ~ 2024-12-31
17,407 GBP2023-01-01 ~ 2023-12-31
Average Number of Employees
12024-01-01 ~ 2024-12-31
12023-01-01 ~ 2023-12-31
Trade Debtors/Trade Receivables
Current
12,568 GBP2024-12-31
35,836 GBP2023-12-31
Prepayments/Accrued Income
Current
15,343 GBP2024-12-31
15,495 GBP2023-12-31
Debtors
Amounts falling due within one year, Current
27,911 GBP2024-12-31
51,331 GBP2023-12-31
Amounts owed to group undertakings
Current
174,632 GBP2024-12-31
341,686 GBP2023-12-31
Corporation Tax Payable
Current
4,174 GBP2024-12-31
Accrued Liabilities
Current
14,667 GBP2024-12-31
14,704 GBP2023-12-31

  • BRIDGING PHARMA LTD
    Info
    Registered number 09359212
    3rd Floor 9 St. Clare Street, London EC3N 1LQ
    PRIVATE LIMITED COMPANY incorporated on 2014-12-17 (11 years 3 months). The company status is Active.
    The last date of confirmation statement was made at 2025-02-25
    CIF 0
child relation
Offspring entities and appointments 0
  • Not found in our database.

The content of this website is protected by AgonGuard.

© 2022- Polylogarithmic Technology Ltd (Registered in England and Wales No. 14256313). All rights reserved.

Contains public sector information retrieved at 9 February 2026 and licensed under the Open Government Licence v3.0.